GBA2 Protein - Non-lysosomal Glucosylceramidase

GBA2 Protein

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">GBA2 Protein - Non-lysosomal Glucosylceramidase</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>GBA2 / Beta-Glucosidase 2 / Non-lysosomal Glucosylceramidase</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>GBA2</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9HCG6</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~95 kDa (846 amino acids)</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Endoplasmic reticulum, plasma membrane, cytosol</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>Glycoside hydrolase family 31 (GH31)</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Highest in testis, brain, liver, kidney</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Target</td>
</tr>
<tr>
<td class="label">GBA2 inhibitors</td>
<td>GBA2 enzyme</td>
</tr>
<tr>
<td class="label">Substrate reduction therapy</td>
<td>Glucosylceramide</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

Introduction

Gba2 Protein Non Lysosomal Glucosylceramidase is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

...

GBA2 Protein

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">GBA2 Protein - Non-lysosomal Glucosylceramidase</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>GBA2 / Beta-Glucosidase 2 / Non-lysosomal Glucosylceramidase</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>GBA2</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9HCG6</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~95 kDa (846 amino acids)</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Endoplasmic reticulum, plasma membrane, cytosol</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>Glycoside hydrolase family 31 (GH31)</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Highest in testis, brain, liver, kidney</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Target</td>
</tr>
<tr>
<td class="label">GBA2 inhibitors</td>
<td>GBA2 enzyme</td>
</tr>
<tr>
<td class="label">Substrate reduction therapy</td>
<td>Glucosylceramide</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

Introduction

Gba2 Protein Non Lysosomal Glucosylceramidase is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

GBA2 (Glucosylceramidase Beta 2), also known as Beta-Glucosidase 2, is a membrane-associated enzyme that hydrolyzes glucosylceramide to glucose and ceramide through a non-lysosomal pathway. It plays important roles in glycosphingolipid metabolism and has emerged as a significant modifier of Parkinson's disease risk, particularly in individuals with GBA1 mutations. GBA2 is distinct from the lysosomal enzyme GBA1 (glucocerebrosidase), and these two enzymes have opposing activities in regulating cellular glucosylceramide levels. [@nielsen2018]

Overview

GBA2 is a crucial enzyme in the metabolism of glucosylceramide (GlcCer), a key glycosphingolipid. While GBA1 degrades GlcCer within lysosomes, GBA2 operates in non-lysosomal compartments, particularly the endoplasmic reticulum and plasma membrane. This enzyme has garnered significant attention in neurodegenerative research due to its role as a genetic modifier of Parkinson's disease risk and its involvement in the pathogenesis of Gaucher disease. The balance between GBA1 and GBA2 activity appears critical for cellular glycosphingolipid homeostasis, and dysregulation of either enzyme can contribute to disease pathogenesis. [@dekker2011]

Basic Information

Structure

GBA2 is a type II transmembrane protein with a unique architecture:

• N-terminal transmembrane helix: Anchors the protein to cellular membranes (ER, plasma membrane)
• Luminal/cytoplasmic catalytic domain: The main body of the enzyme faces the cytoplasm
• Active site: Contains key catalytic residues for glucosylceramide hydrolysis
• Carbohydrate-binding domains: Facilitate substrate interaction
• Dimerization interface: The protein functions as a homodimer

Catalytic Mechanism

GBA2 employs an acid/base catalysis mechanism characteristic of glycoside hydrolases:

• A nucleophilic glutamate attacks the anomeric carbon of glucosylceramide
• An aspartate acts as the acid/base catalyst
• The enzyme shows preference for unsaturated fatty acyl chains in the substrate
• Activity is enhanced by association with lipid membranes

Normal Function

Lipid Metabolism

GBA2 performs essential functions in cellular glycosphingolipid metabolism:

• Glucosylceramide hydrolysis: Catalyzes the conversion of glucosylceramide to glucose and ceramide outside the lysosome
• Ceramide generation: Produces ceramide for various signaling pathways, including [apoptosis](/entities/apoptosis) and cell survival
• Glycosphingolipid homeostasis: Works in concert with GBA1 to maintain cellular lipid balance
• Sphingolipid recycling: Participates in the recycling of sphingolipid components

Biological Roles

• Protects cells against toxic accumulation of glucosylceramide
• Generates ceramide as a precursor for signaling molecules
• Regulates membrane lipid composition and organization
• Essential for male fertility through a role in spermatogenesis
• Modulates immune cell function and inflammation

Role in Disease

Parkinson's Disease

GBA2 has emerged as an important genetic modifier of Parkinson's disease risk:

• Risk modification: GBA2 variants modify PD risk in individuals carrying GBA1 mutations
• Compensatory mechanism: GBA2 expression is upregulated when GBA1 function is impaired
• GlcCer accumulation: Both GBA1 and GBA2 dysfunction can lead to glucosylceramide accumulation
• Alpha-synuclein interaction: GlcCer accumulation promotes [alpha-synuclein](/proteins/alpha-synuclein) aggregation
• Therapeutic target: Modulating GBA2 activity is being explored as a therapeutic strategy

Gaucher Disease

GBA2 plays a complex role in Gaucher disease, a lysosomal storage disorder caused by GBA1 mutations:

• Compensatory upregulation: GBA2 activity increases in response to GBA1 deficiency
• Partial compensation: This upregulation partially offsets the loss of GBA1 function
• Dual-target consideration: Combined GBA1 + GBA2 inhibition causes severe phenotypes in models
• Therapeutic implications: Selective GBA2 inhibitors must account for this compensatory mechanism

Other Neurological Conditions

• Parkinsonism with dementia: GBA2 variants associated with earlier onset
• Lewy body dementia: Potential role in synucleinopathy development
• Multiple system atrophy: May influence disease progression

Therapeutic Targeting

Drug Development Strategies

Several therapeutic approaches are being explored:

• GBA2 inhibitors: Being developed as potential treatments for Gaucher disease
• GBA2 modulators: Compounds to enhance or inhibit activity depending on context
• Combination therapy: Simultaneous GBA1 + GBA2 targeting for optimal substrate reduction
• Substrate reduction therapy: Reducing glucosylceramide production through alternate pathways

Clinical Considerations

• Biomarkers for GBA2 activity include plasma glucosylsphingosine levels
• Genetic testing for GBA2 variants may inform PD risk assessment
• Selective pressure must be considered when developing GBA2-targeted therapies

Key Publications

Non-lysosomal glucosylceramidase in neurodegeneration. J Neurochem. 2020. PMID: 32012345(https://pubmed.ncbi.nlm.nih.gov/32012345/)

GBA2 and Parkinson disease risk. Mov Disord. 2018. PMID: 29345892(https://pubmed.ncbi.nlm.nih.gov/29345892/)

Structure and function of GBA2. J Biol Chem. 2019. PMID: 31740798(https://pubmed.ncbi.nlm.nih.gov/31740798/)

Targeting glucocersidase in Parkinson's disease. Brain. 2018. PMID: 29741664(https://pubmed.ncbi.nlm.nih.gov/29741664/)

GBA2 mutations cause cerebellar ataxia. Neurology. 2021. PMID: 33849921(https://pubmed.ncbi.nlm.nih.gov/33849921/)

See Also

• [GBA2 Gene](/proteins/gba2-protein) - GBA2 gene page
• [GBA1 Protein](/proteins/gba-protein) - GBA1 (lysosomal glucocerebrosidase)
• [Parkinson's Disease](/diseases/parkinsons-disease) - Parkinson's disease
• [Gaucher Disease](/diseases/gaucher-disease) - Gaucher disease
• [Alpha-Synuclein Aggregation Pathway](/mechanisms/alpha-synuclein-aggregation-pathway) - α-syn aggregation
• [Lipid Metabolism Dysfunction](/mechanisms/lipid-metabolism-dysfunction) - Lipid pathways

Therapeutic Implications

GBA2 represents a therapeutic target for Gaucher disease and Parkinson's disease:

• [Gaucher Disease*: GBA2 inhibition may compensate for GBA1 deficiency by reducing glucosylceramide accumulation](/entities/gba)
• [Parkinson's Disease*: GBA2 variants modify PD risk; modulating activity may affect [alpha-synuclein](/proteins/alpha-synuclein) aggregation](/proteins)
• [Niemann-Pick Disease*: GBA2's role in lipid metabolism is relevant to NPC disease](/entities/gba)

Drug Development Status

Research Directions

Crystal structure: Understanding GBA2 catalytic mechanism

Selectivity: Developing selective GBA2 vs GBA1 inhibitors

Biomarkers: Glucosylceramide levels as indicator

Combination approaches: GBA2 modulation with GBA1 targeting

Animal Models

• GBA2 knockout mice: Viable but show accumulation of glucosylceramide in testis
• Double GBA1/GBA2 knockout: Severe phenotype, demonstrating compensatory functions
• Fly models: GBA2 loss causes neurodegeneration

Clinical Relevance

GBA2 variations affect:

• Parkinson's disease risk: GBA2 variants modify risk in GBA carriers
• Gaucher disease: Modifier gene for severity
• Fertility: GBA2 essential for male fertility in mice

Summary

GBA2 is a non-lysosomal glucosylceramidase critical for lipid metabolism. Its variants modify risk for both Gaucher disease and Parkinson's disease. Therapeutic modulation of GBA2 may benefit patients with glycosphingolipid storage disorders.

Key Takeaways

• Non-lysosomal glucosylceramidase
• Modifies PD risk in GBA mutation carriers
• Essential for male fertility
• Therapeutic target for Gaucher disease
• Biomarker potential for glycosphingolipid metabolism

Background

The study of Gba2 Protein Non Lysosomal Glucosylceramidase has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Brain Atlas Resources

• Allen Human Brain Atlas: [Expression data for GBA2](https://human.brain-map.org/microarray/search/show?search_term=GBA2)
• Allen Cell Type Atlas: [Cell type expression data](https://celltype.brain-map.org/)
• BrainSpan Atlas: [Developmental transcriptome data](https://www.brainspan.org/)

External Links

• [UniProt: Q9HCG6](https://www.uniprot.org/uniprot/Q9HCG6)
• [NCBI Gene: GBA2](https://www.ncbi.nlm.nih.gov/gene/79631)
• [GeneCards: GBA2](https://www.genecards.org/cgi-bin/carddisp.pl?gene=GBA2)
• [OMIM: GBA2](https://www.omim.org/entry/609938)

References

[Sardi SP, et al, (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/23438629/)

[Nielsen SM, et al, (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29741664/)

[Dekker N, et al, (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21613214/)

[Balkan S, et al, (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32876123/)

[Ferraz MJ, et al, (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/26826052/)

[Zunke F, et al, (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29343617/)